Serum Glycan Analysis in Breast Cancer
- To profile serum glycan biomarkers in women with metastatic stage IV breast cancer,
healthy controls, and patients with noncancer medical illness.
- To determine whether serial serum glycan biomarkers correlate with response of
metastatic disease to treatment.
OUTLINE: This is a multicenter study.
Blood is collected from patients with metastatic breast cancer, patients with noncancerous
illness, and healthy volunteers. Samples are analyzed for serum glycan biomarkers by
matrix-assisted laser desorption/ionization (MALDI) and Fourier transform ion-cyclotron
resonance mass spectrometry (FT ICR MS) methods.
Blood samples are collected every 3 months for up to 18 months from patients with metastatic
breast cancer. Patients without cancer have a single sample collected.
Profiling serum glycan biomarkers in patients with metastatic breast cancer, healthy controls, and patients with noncancer medical illness
up to 18 months
Helen K. Chew, MD
University of California, Davis
United States: Institutional Review Board
|University of California Davis Cancer Center||Sacramento, California 95817|